Harris Gelbard Receives International Award for Neurovirology Research
Tuesday, September 13, 2016
Harris “Handy” Gelbard, M.D., Ph.D., director of the Center for Neural Development & Disease, is slated to receive the Hilary Koprowski Prize in Neurovirology at this year’s International Symposium on Molecular Medicine and Infectious Disease at Drexel University. Gelbard will be recognized for developing an unconventional drug that shows promise in treating brain disorders associated with HIV.
Gelbard’s drug, URMC-099, calms the immune system when it goes awry, as happens in HIV Associated Neurocognitive Disorder (HAND). In HAND, immune reactions to HIV particles in the brain damage nerve cells and cause dementia. Because patients affected by HAND also have HIV, it was imperative that URMC-099 not interfere with the antiretroviral drugs that keep HIV-positive patients alive.
Study Details Source of Mental Problems Associated with MS
Tuesday, January 26, 2016
A study out today sheds new light on multiple sclerosis (MS), specifically damage in the brain caused by the disease that may explain the slow and continuous cognitive decline that many patients experience. The findings, which appear in the Journal of Neuroscience, show that the brain’s immune system is responsible for disrupting communication between nerve cells, even in parts of the brain that are not normally considered to be primary targets of the disease.
“This study identifies for the first time a new disease mechanism in MS which causes damage to neurons independent of the loss of white matter and demyelination that is the hallmark of the disease,” said the lead author, neurologist Matthew Bellizzi, M.D., Ph.D., with the Center for Neural Development and Disease at the University of Rochester Medical Center (URMC). “This damage represents another component of the disease and one that is not prevented by the current immunosuppressive drugs employed to treat MS.”Read More: Study Details Source of Mental Problems Associated with MS